clinical trial · NCT06567080
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
B-cell TumorsAutoimmune DiseasesLupus Erythematosus, SystemicLarge B-cell LymphomaJWCAR201
brief summary
JWCAR201 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR201 in patients with B cell driven hematology malignancy and autoimmune diseases
started
Sep 1, 2024
primary completion
Sep 1, 2025
completion
Mar 1, 2027
last updated
Aug 22, 2024
detailed description
JWCAR201 is a CD19/CD20 CAR-T product. By targeting both CD19 and CD20, it is expected to overcome some limitations with CD19 or CD20 single target products. In this study, patients with B cell driven hematology malignancy and autoimmune diseases will be enrolled to receive JWCAR201. PK/PD properties and preliminary efficacy and safety will be evaluated. Each subject will receive JWCAR201 once and is followed up for up to 2 years.
official title
An Open Label, Single Arm Study to Evaluate JWCAR201 Treating B Cell Driven Hematology Malignancy and Autoimmune Diseases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol